Open AccessHigh Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
Author(s) -
Philippe J. Zamor,
Ashley Brown,
Douglas E. Dylla,
John Dillon,
Anne F Luetkemeyer,
Jordan J. Feld,
David Mutimer,
Reem Ghalib,
Eric D. Crown,
Sandra Lovell,
Yiran Hu,
Christophe Moreno,
David R. Nelson,
Massimo Colombo,
Georgios Papatheodoridis,
Juergen Rockstroh,
Richard Skoien,
Eric Lawitz,
Ira M. Jacobson
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000001332
Subject(s) - medicine , dosing , population , clinical trial , post hoc analysis , viral load , cirrhosis , hepatitis c , hepatitis c virus , gastroenterology , virus , immunology , environmental health
Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on efficacy in patients with suboptimal adherence, particularly with shorter treatment durations. These post hoc analyses evaluated adherence (based on pill count) in patients prescribed 8- or 12-week G/P, the impact of nonadherence on sustained virologic response at post-treatment week 12 (SVR12), factors associated with nonadherence, and efficacy in patients interrupting G/P treatment.